From the helm: Argenica Therapeutics (ASX:AGN), Dr. Liz Dallimore, CEO & MD

Interview Series 1st October 2025

Join Bell Financial Group's Senior Market Analyst Grady Wulff as she sat down with Dr. Liz Dallimore, CEO & MD of Argenica Therapeutics (ASX:AGN) to discuss the company's lead drug candidate ARG-007, and its pathway to commercialisation to become the world's first neuroprotective drug for the protection of brain cells post stroke or catastrophic brain injury.

In this interview, Liz covers:

• (0:40) an overview of Argenica Therapeutics (ASX:AGN)

• (1:28) details on ARG-007, including its mechanism in protecting brain cells after stroke

• (4:59) expected runway, and potential need for additional financing pre-Phase 3

• (8:42) other drug candidates in development within Argenica’s pipeline

• (10:01) expected investor news flow over the next 12 months

Note: This interview was filmed on 24 September 2025.